COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Allied Universal Announces Increase to Previously Announced Cash Tender Offer of its 6.625% Senior Secured Notes due 2026
Allied Universal increases the Maximum Tender Amount and Total Consideration for its senior secured notes due 2026, financing the Tender Offer through a new offering. The Tender Offer is set to expire on February 29, 2024, and is subject to numerous terms and conditions. For more information, visit www.aus.com -
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: SFC Energy AG: Forecast for financial year 2023 exceeded
SFC Energy AG expects to exceed forecasted key financial figures for 2023 with sales of around EUR 118 million and adjusted EBITDA of around EUR 15 million, mainly due to improved product mix and additional sales in Q4 -
COMMUNIQUÉ DE PRESSE
Gladstone Investment Corporation Earnings Call and Webcast Information
Gladstone Investment Corporation (Nasdaq: GAIN) announces Third Fiscal Quarter Ended December 31, 2023 Earnings Call & Webcast on February 7, 2024 at 8:30 a.m. ET. For further details, please visit their website -
-
COMMUNIQUÉ DE PRESSE
Boron One Granted New Exploration License as it Progresses Through Exploitation Approvals
Boron One Holdings Inc. has been granted a new 3-year exploration license by the Serbian Ministry of Mining and Energy for its Piskanja Boron Project, ensuring continued exclusive rights and potential expansion of the known mineral resource. The company is progressing through the mineral exploitation approval process for Piskanja -
COMMUNIQUÉ DE PRESSE
Labor Smart Inc., LTNC, Next Gen Beverages Launches New eSports Division
Labor Smart, Inc. announces the launch of its new eSports Gaming Division through its subsidiary, Next Gen Beverages, offering opportunities for gamers and aligning with the growing eSports phenomenon. The company encourages gaming enthusiasts to join the affiliate program and learn about the innovative LOCK'DIN products -
COMMUNIQUÉ DE PRESSE
Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis
Tharimmune, Inc. completes first patient dosing in Phase 1 clinical trial for TH104, an oral thin film targeting liver-related and pruritogenic inflammatory conditions. Topline data expected in 2Q24 with full readout shortly after. Company fully funded into 2025 for Phase 1 and 2 readouts -
COMMUNIQUÉ DE PRESSE
Form 8.3 - The Vanguard Group, Inc.: abrdn Property Income Trust Limited
The Vanguard Group, Inc. discloses 1.05% interest in abrdn Property Income Trust Limited's 1p ordinary class of relevant securities. Details of the disclosure are provided in Form 8.3 submitted on 5th February 2024
